king
initi outperform rate tp siegfri global
contract develop manufactur organis specialis
product drug substanc product small molecul
asept fill space see signific growth opportun base
favour industri condit believ siegfri under-valued versu
peer base strong financi perform accompani report
also initi specialis peptid
top-lin tailwind
outsourc manufactur market expect outgrow pharma market
compound-annual-growth-rate vs pharma accord
result healthcar industri also fragment biggest
oper gener sale siegfri top believ
critic size necessari build long-last busi relationship
expect sale grow compound-annual-growth-rate
margin growth strong siegfri record ebitda margin
increas dividend
expect trend continu driven invest digitis
technolog given simpler molecular structur physic properti
small molecul vs complex one peptid see potenti
siegfri optimis oper via data analyt simul
catalyst ceo wienand present cs swiss mid-cap confer
novemb public financi result march risk
outsourc trend slow neg impact siegfri order book reaction
us opioid epidem currenc risk sale sfr
valuat tp averag multiple-bas valuat
ev/ebitda discount cash flow wacc
lt growth credit suiss holt warrant price
valuat metric
number share
price month
price rel chart measur perform
swiss market ind close
spot exchang rate
suiss seek busi compani cover research report result investor awar
firm may conflict interest could affect object report investor consid report
singl factor make invest decis
siegfri swiss-bas activ product drug
dosag form steril fill compani oper facil
switzerland germani franc malta unit state china
profit tax
associ
chang work capit
cash non-cash item
flow oper
free cash-flow firm
flow invest
issuanc retir debt
cash-flow financ
chang net cash/debt
scenario assum top line growth line lonza
pharma biotech busi
versu base case
also assum ev/ebitda multipl cse
multipl lonza
grey scenario assum top line growth
due unfavor currenc movement well fewer
new project due decreas outsourc manufactur biotech
compani use ev/ebitda multipl vs
base case align lower top line growth compar
base case
price rel chart measur perform swiss market
ind close
spot exchang rate
net debt start
chang net debt
net debt end
total equiti liabil
share wtd average mn
ratio valuat
net debt ebitda
figur overview highli fragment
figur sale develop product
figur siegfri dividend develop
net debt/ebitda ex hybrid incl pension
charl martineau pm univers toronto tabl content
siegfri credit suiss holt
initi siegfri outperform rate target price per share
siegfri pure-play contract develop manufactur organis
focus develop manufactur drug substanc ds drug product dp
within small molecul asept fill space siegfri world-wide footprint
sale market manufactur
figur compani snapshot decemb
cost
sale
sale
ds small molec drug discoveri
ingredi drug caus effect
chemic whose product ownership use
strictli regul
ex opiat deriv use pain killer mainli
cancer treatment api methadon
 nicotin use addict therapi sfzn
global market leader categori
dp matur segment slower compound-annual-growth-rate ds us
cgmp-compliant scaling-up product
clinic materi mass product
packag finish product
steril asept fill among demand
process pharmaceut manufactur
see consider growth opportun siegfri base promis industri
condit support top-lin growth also see siegfri under-valued
versu peer base strong financi perform
top-lin tailwind industri momentum
contract manufactur outgrow pharma market
contract manufactur industri estim outgrow pharma industri
per annum compound-annual-growth-rate pharma vs outsourc
manufactur driven on-going shift pharma compani focu core
compet result divest manufactur logist
activ accord corpor advisori firm result healthcar furthermor
manufactur market fragment top player account revenu
mani privat compani go phase consolid
think potenti offer addit opportun siegfri grow
siegfri one top player revenu believ alreadi
achiev critic size necessari build long-last busi relationship big
pharma siegfri also histori success growth acquisit
current manag team strong track record privat equiti
compani suffici fund financ possibl acquisit opportun
although consid hybrid capit debt manag well
financi institut subsum equiti henc signific room increas
manufactur commerci activ ingredi api
small molecul alway play domin role clinic commerci
pharma market estim small molecul continu account biggest
market share outsourc commerci manufactur api market current around
wherebi gener api make largest share assumpt support
fact fda approv highest number nce past
clinic small molecul manufactur outgrow commerci
commerci small molecul manufactur market grow mid-singl digit
clinic small molecul manufactur market grow high-singl digit
see siegfri well posit thank global network enabl offer
tailor-mad product exclus client also standardis product multipl
client network also help siegfri creat busi relationship exceed
length product life-cycle offer product clinic commerci
manufactur within commerci brand gener type
strong growth steril inject
global steril inject drug market reach size approxim
expect grow compound-annual-growth-rate howev
larg market size mainli due high price biolog therapi rather
aseptic/steril manufactur fill challeng requir care
plan highli train personnel well specialis facil equip
factor present high barrier entri
siegfri enter field acquir facil irvin california us
specialis steril asept fill specif complex biolog
acquir hameln facil germani specialis mass product steril fill
although field still repres small part drug product dp categori
cse revenu repres dp categori total
revenu forecast highest compound-annual-growth-rate product
categori addit manag look grow space acquir small-scal
biolog manufactur asset ds asept fill capac dp europ
prefer us
impact siegfri acquisit basf api busi fade
siegfri abl increas ebitda margin vs
also increas dividend vs
gener strong vs
expect trend continu come year driven disciplin control
expens market sale well furthermor expect compani
invest digitis technolog strengthen global network lower
complex regulatori oper procedur precis see
follow area contribut optimis effici ultim increas margin
data analyt appli exist busi model spot bottleneck
product logist process optimis global network
data analyt appli futur earn opportun structur
inform order facilit strateg decis
expans
micronis product
technolog strengthen compani posit strateg partner
ultim increas price power
progress laboratori autom process develop safeti qualiti
reduc cost modern softwar make possibl simul chemic
physic process product scale reduc scale-up risk
increas product qualiti process safeti
centralis strateg procur function purchas raw materi allow
compani minimis risk regard raw materi price suppli
ultim posit impact profit
due simpler molecular structur physic properti small molecul
compar complex api peptid see small molecul gener
suit data analyt simul peptid data analyt
simul use optimis product process see margin
expans potenti siegfri
also believ increas capac utilis nantong china facil
far capac utilis increas compani
profit economi scale
compar peer estim siegfri abl increas ebitda
margin vs histor averag peer averag ebitda margin
expect increas consensu forecast
disciplin fund alloc lead strong gener continu
strong gener also possibl due siegfri disciplin fund
alloc principl goal maintain strong balanc sheet financi
flexibl compani prioritis use cash follow order
reinvest organ growth
de-lever balanc sheet
organ sale grow compound-annual-growth-rate expect capital-expenditure level grow
compound-annual-growth-rate decreas sale level rel
low expect much impact gener furthermor moder dividend
pay-out ratio net profit oper cash flow support invest
similar comparison ebitda margin believ siegfri better
dividend yield peer
acquisit import part siegfri growth strategi note risk
siegfri may identifi right target right time target compani could
overvalu also believ mani potenti target candid could privat
family-own compani bring addit challeng
siegfri maintain long-last busi relationship custom reduc
volatil busi risk relationship may end product
reach end life-cycle due custom strateg re-orient
siegfri market leader manufactur opiat deriv given opioid epidem
us believ fda like cautiou futur drug
approv categori respons percept doctor increas
lead decreas opioid prescript even though siegfri mainli manufactur
opiat deriv use pain manag cancer treatment categori
see lower risk remain risk order book could affect
current pharma biotech industri trend toward outsourc develop
manufactur activ howev pharma compani start develop
manufactur certain drug exampl fast-grow biolog
abl negoti regul and/or keep price power could impact siegfri
siegfri client base outsid switzerland see figur
risk currenc fluctuat could impact siegfri revenu howev siegfri use
natur hedg minimis impact
siegfri maintain manufactur facil nantong china see risk
current trade war us china could impact part siegfri sale
howev see high risk siegfri maintain global network
product facil henc abl produc product outsid china
standard besid accord manag siegfri also produc
chines market importantli cost api small magnitud
compar cost final drug probabl manag
perceiv concern us pharma compani respect
figur show estim versu consensu forecast ahead consensu
mention year
due fx unpredict assum unchang fx rate furthermor assum
two hybrid bond paid back first call date octob
hybrid bond interest rate octob
hybrid bond interest rate assum hybrid bond paid
back partli cash partli new loan lower interest rate
although compani issu exact guidanc guid top-lin growth
least mid-singl digit unchang foreign exchang rate continu
improv ebitda margin full-year mid-term manag
guid profit organ growth line market ambit outgrow
market select value-accret interpret statement
sale ebitda margin origin state
seen figur sale estim interpret
compani guidanc consensu howev ebitda margin
compani guidanc consensu
believ compani potenti exceed sale guidanc higher
sale later translat better margin howev believ effect visibl
believ tough increas margin
compani still rel new certain region china divis
steril fill like hamper rapid margin increas
figur compani guidanc cs interpret vs cse consensu
target price per share base equally-weight blend peer
multiples-bas dcf-deriv valuat peer multipl
valuat valu siegfri ev/ebitda line peer
median dcf use beta wacc long-term growth rate
ev/ebitda
potenti up/down current share price
price septemb credit suiss estim
peer multipl valuat per share see figur valu group
ev/ebitda line peer median
peer use
believ lonza cambrex recipharm closest list
peer siegfri key characterist compani outlin
lonza revenu oper incom net incom
swiss-bas headquart basel lonza oper two segment
pharma biotech nutrit specialti ingredi provid product develop
manufactur servic pharma biotech industri includ organ
fine perform chemic custom manufactur biopharmaceut
chemic synthesi small-molecul api lonza site
offic across globe fte annual sale chf
us-bas headquart new jersey compani provid
product servic gener small molecul api intermedi
compani maintain cgmp current manufactur practic
manufactur facil us europ cambrex fte
gener annual sale usd
note cambrex acquir permira fund global invest
firm august permira paid premium stock price
day deal announc total includ cambrex
kept cambrex consensu estim report broader comparison
us-bas headquart new jersey compani provid servic
product drug biolog consum anim health includ drug pre-
formul formul analyt test clinic commerci manufactur
clinic packag suppli chain regulatori consult catal maintain site
across globe fte annual sale usd
swedish headquart stockholm oper divid
two area manufactur servic develop technolog includ
analyt develop stabil studi clinic suppli compani
maintain product facil europ india develop site sweden
israel us recipharm fte sale equival
revenu oper incom net incom sfr
specialis develop manufactur peptid complex
organ molecul activ pharmaceut ingredi api well innov
biochem research purpos
use ev/ebitda multipl
price septemb credit suiss estim lonza siegfri i-b-e-s forecast compani
price septemb credit suiss estim lonza
siegfri i-b-e-s estim compani
price septemb credit suiss estim lonza
siegfri i-b-e-s estim compani
use ev/ebitda multipl
assum siegfri perform deterior compar
believ siegfri revenu continu grow
ebitda margin improv versu justifi use
ev/ebitda multipl
besid given similar product end market describ believ
reason use peer median ev/ebitda multipl shown peer
comparison tabl believ siegfri look inexpens compar
peer seem unjustifi us given better expect perform
comparison siegfri versu peer see page
dcf-base valuat siegfri per share premis upon
period explicit estim
use year explicit estim line averag
develop period drug well life-cycle approv drug
sale compound-annual-growth-rate line industri compound-annual-growth-rate
ebit margin increas
work capital/sal capex/sal decreas time
howev siegfri acquir anoth compani expect ratio increas
temporarili turn back histor level integr implement
capex/depreci decreas
tax rate line guidanc
beta equiti risk premium wacc
assum termin growth rate line estim long-run
growth rate small molecul
tax adj ebit
chang work capit wc
chang asset
invest intang acquisit
year
equiti valu per share sfr
share
period explicit estim
year explicit estim
debt
equiti
capit wacc
work capit sale
impli equiti valu sfr/sh
impli equiti valu sfr/sh
end period ebitda margin
valuat per share scenario look siegfri
would valu growth characterist lonza pharma biotech
busi see compar siegfri busi appli top line
growth lonza pharma biotech busi vs
base case siegfri also assum
ev/ebitda multipl multipl lonza
grey valuat per share scenario assum top-lin growth
due unfavor currenc movement well fewer new
project due decreas outsourc manufactur biotech compani use
ev/ebitda multipl vs base case align lower top line
growth compar base case
siegfri credit suiss holt
holt methodolog use proprietari perform measur known
return invest cfroi approxim econom return
estim averag real intern rate return earn firm portfolio
project constitut oper asset firm cfroi directli compar
real cost capit investor real discount rate see firm creat
econom wealth remov account inflat distort cfroi allow
global compar across sector region time also comprehens
metric tradit roe
siegfri holt
siegfri sub-cost capit busi histori return
averag past five year econom profit remain neg
trend improv sinc market cap increas period
price
creat market-impli scenario siegfri default five-year window
assum long term real discount rate weight peer discount rate use
consensu estim start point siegfri price top line
growth flat margin suggest cfroi improv
pink bar asset growth reach blue bar next five year see
achiev
credit suiss forecast holt
figur link forecast credit suiss holt model
holt suggest warrant price chf line target price
chf upsid holt compar current price despit fade top
line year
margin trajectori expect continu improv due optimis infrastructur
logist effici invest technolog
charl martineau pm univers toronto sensit scenario sale margin suggest upsid potenti
downsid risk holt valuat
sale growth parallel point chang forecast
price book
cfroi discount rate
asset growth
credit suiss holt cfroi holtar trademark regist trademark credit suiss group ag affili unit state countri
price septemb credit suiss estim credit suiss holt
top-lin tailwind industri momentum
contract manufactur outgrow pharma market
last year patent cliff price pressur forc pharma compani rethink
busi model focu core compet drug discoveri ad
valu exist drug process streamlin result number divest
manufactur logist busi turn creat growth opportun
phenomenon on-going total pharmaceut outsourc
manufactur market expect outgrow pharma market per annum
compound-annual-growth-rate market vs pharma market accord
result therefor cdmo captur growth outsourc
underli pharma industri driven econom growth demograph chang
grow oncolog market technolog progress name
cdmo could benefit opportun howev industri fragment
top includ siegfri account total
market competit consolid take place consolid challeng
high number privat compani sector may neg impact
valuat compani pace acquisit
figur overview highli fragment competit market
outsourc trend move toward one-stop-shop allow big pharma
place one order product drug product instead collabor
differ supplier one api one drug product impli
pharma compani fewer longer term busi relationship cdmo
give larg cdmo clear advantag broader portfolio offer
think siegfri look well posit develop
one top compani siegfri alreadi critic size enabl
collabor import big pharma compani maintain global network
manufactur facil offer broad portfolio product across whole drug
manufactur suppli chain network enabl siegfri produc product
differ price rang brand gener attract varieti client
one product life cycl siegfri theoret manufactur
brand drug patent expir also gener version drug
siegfri histori success acquisit see page figur
transform compani toward one-stop-shop manag team
strong record privat equiti ceo head siegfri team
almost eight year cfo held sever senior financ posit within privat
equiti industri benefici industri consolid
manufactur commerci api small molecul
small molecul alway import pharma industri
present almost everi phase clinic develop compar biolog
peptid formul pill tablet make easi transport
manufactur lower cost moreov favour patient pill
tablet easier administ iv inject exampl
total potenti commerci manufactur market assum full outsourc
cdmo account around one-quart market
accord pharma review outsourc manufactur
review estim total outsourc market commerci clinic
grow small molecul commerci
suppli account market revenu
figur breakdown outsourc manufactur market
believ import domin small molecul continu
demonstr fact fda approv highest number small
molecul past year
similarli drug receiv anda approv offer opportun cdmo
manufactur gener api
small molecul commerci manufactur brand gener estim grow
per annum accord result healthcar slightli
contract manufactur categori howev high market share
subgroup ensur import
clinic small molecul manufactur outgrow commerci
commerci contract manufactur highest market share within small
molecul contract manufactur grow mid-singl digit small molecul
discoveri market expect grow compound-annual-growth-rate driven high
amount synthet api within phase ii pipelin pharma
compani like driven increas outsourc owe lower-cost
manufactur fewer risk term capital-expenditure shorter timelin accord mordor
interestingli underli growth small molecul develop partli driven
rise ai drug discoveri simpler molecular structur interact pattern
small molecular drug develop make much access ai compani
exampl develop biolog led ventur capit vc ai
money invest small molecul drug develop drug
subcategori figur figur
figur drug discoveri focu ai startup
figur estim amount disclos vc
fund us period
togeth
small molecul
advanc manufactur pharma industri well price sensit
time pressur pharma compani continu drive clinic small molecul
siegfri global diversifi facil respond differ type custom
demand brand gener apis/drug product standardis commerci
product tailor-mad clinic product notabl siegfri hq signific
depart locat strateg advantag locat close two world
top scientif univers ethz epfl swiss big pharma compani
proxim univers enabl siegfri attract talent latest know-how
proxim big pharma compani encourag strong long-stand
strong growth steril inject
even though first biolog drug humanis insulin introduc
consider invest time resourc requir new promis
market reach approxim accord market research
expect grow compound-annual-growth-rate reach almost
howev larg market size mainli attribut high price
biolog therapi rather volum
contrast small molecul biolog much larger molecul molecular
weight vs small molecul gener sensit heat easili degrad
usual produc mean biotechnolog genet engin organ
highli specif drug gener lower toxic howev cross cell
membran administ oral need administ
via parenter ophthalm inhal otic rout method administr carri
increas risk infect molecul biolog pass bodi
natur barrier defens unlik oral administr reason fda requir
product deliv oral label steril product
aseptic/steril manufactur fill challeng requir care plan
highli train personnel specialis facil equip creat high
barrier entri
siegfri step field acquir facil irvin california us
specialis steril asept fill specif complex biolog
broaden capac specialis acquir hameln facil germani
specialis mass product steril fill although field still repres
small part drug product categori cse revenu repres
dp categori total revenu forecast categori
highest compound-annual-growth-rate page product categori
accord manag siegfri interest grow space
acquir small-scal biolog manufactur asset ds asept fill capac
dp europ prefer us
siegfri consist increas ebitda margin sinc acquisit basf
pharmaceut busi expect trend continu come year
driven improv disciplin expens market sale
expect compani increas invest digitis strengthen global
network lower complex regulatori oper procedur expect
visibl proport lower growth cog expens
precis expect follow area contribut optimis
oper effici ultim increas margin
data analyt appli exist busi model spot bottleneck within
product logist process optimis global network
data analyt appli futur earn opportun structur
inform order facilit strateg decis
expans
micronis product
technolog strengthen compani posit strateg partner
ultim increas compani price power
progress laboratori autom process develop safeti qualiti
reduc cost modern softwar facilit simul chemic
physic process product scale reduc scale-up risk
increas product qualiti process safeti
centralis strateg procur function purchas raw materi
allow compani minimis risk regard raw materi price
suppli posit effect profit
owe simpler molecular structur physic properti small molecul
compar complex api peptid see greater potenti use data
analyt simul develop product small molecul compar
peptid data analyt simul use optimis product
process expect margin expans potenti siegfri
moreov believ increas capac utilis nantong facil
capac utilis increas compani profit
economi scale
estim siegfri abl increas ebitda margin vs
histor averag peer averag ebitda margin forecast consensu
increas although siegfri histor trade discount fair
valu expect compani trade premium howev given
margin increas expect view premium justifi
specialis peptid product follow differ dynam small
molecul product leav bachem peer comparison use data
compani except siegfri use estim
price septemb credit suiss estim siegfri i-b-e-s
compani
price septemb credit suiss estim siegfri i-b-e-s
compani
continu gener dividend increas
siegfri consist increas dividend keep dividend yield rel
stabl figur show forecast gener vs siegfri peer show
compani perform better peer trade discount
price septemb credit suiss estim siegfri i-b-e-s compani
figur show siegfri gener abil cover dividend
gener strong follow absorpt impact acquisit
basf pharmaceut busi dividend coverag ratio high
charl martineau pm univers toronto figur siegfri dividend develop
believ siegfri continu gener solid dividend payout base
compani histor plan disciplin fund alloc polici page
expect capital-expenditure level increas compound-annual-growth-rate sale vs
organ sale growth compound-annual-growth-rate level rel low
expect much impact gener moder dividend pay-out ratio
net profit oper cash flow support invest thesi
sharehold perspect payment dividend standard
siegfri industri attract compani appear compar under-valued
dividend yield basi
price septemb credit suiss estim siegfri i-b-e-s
compani
price septemb credit suiss estim siegfri i-b-e-s
compani
compani issu concret guidanc term number
siegfri launch transform strategi main goal achiev
critic size defin sale secur compani long-term success
goal achiev acquisit basf api busi
compani book sale
siegfri announc evolv strategi togeth concret medium-
term goal sale ebitda margin higher dividend
evolv strategi respond on-going consolid within industri
promot growth target acquisit within drug product drug substanc
space prefer sterile-fil us acquisit well promot organ
expans biolog drug product invest technolog base small-
full-year compani guid top-lin growth least mid-singl digit
unchang foreign exchang rate continu improv ebitda margin
mid-term manag recent redefin guidanc profit organ growth
line market ambit grow select value-accret
 interpret sale ebitda margin
origin state
forecast vs consensu shown page
compani divid sale two product group drug substanc ds api
intermedi control substanc drug product dp oral dosag form
steril fill ds account sale dp sale
divid custom type multi-cli exclus product siegfri report
split howev assum
divid sale four group add steril fill separ categori
dp rel new categori make littl sens yet divid
group custom type howev siegfri facil mass steril fill
charl martineau pm univers toronto figur estim sale develop product custom type
forecast sale yoy yoy
line compani mid-term guidanc model biggest
growth driver dp steril fill though small absolut number ds
estim sale compound-annual-growth-rate ds sale compound-annual-growth-rate dp
sale compound-annual-growth-rate base follow assumpt
ds exclus cse sale compound-annual-growth-rate base growth rate
assumpt industri develop subcategori compound-annual-growth-rate
small molecul drug discoveri market see page well siegfri site
equip state-of-the-art technolog close world-renown
univers pharma compani proxim client facilit knowledg
transfer improv qualiti speed common project also attract talent
staff posit effect growth busi
ds multi client cse sale compound-annual-growth-rate assum categori
grow group averag believ subcategori face
highest price pressur categori base lower barrier entri
manufactur standardis small molecul moreov siegfri market leader
manufactur opiat deriv believ challeng face opioid
market effect siegfri busi posit side
appreci siegfri facil nantong china allow custom
buy ds lower price
dosag matur market grow compound-annual-growth-rate page
believ siegfri well posit grow industri rate given product
facil high-cost countri tailor-mad exclus project well lower-
cost countri mass product
dp steril fill cse sale compound-annual-growth-rate siegfri facil
complex exclus project also mass product believ siegfri global
network intent invest technolog help grow categori
group industri averag steril inject compound-annual-growth-rate page
besid manag announc intent expand categori base
siegfri histori abl acquir size believ categori
potenti reach even higher forecast growth howev account
smallest amount sale absolut number expect contribut lowest
amount absolut term despit high growth rate
siegfri hedg currenc rather use natur hedg approach
dampen fx fluctuat compani favour growth us therefor assum
sale usd futur
figur sale currenc
ebitda compound-annual-growth-rate estim mean expect margin grow faster
sale ebitda margin vs ebitda margin
estim base belief compani increas gross margin
effici capac global network
utilis believ digitis autom also lead
effici process describ page
compani make acquisit see margin come
accordingli howev base histor perform expect rel fast margin
figur ebitda ebitda margin develop
balanc sheet cash flow
end gross debt amount consist non-
current financi liabil hybrid capit pension liabil
relat syndic credit agreement avail
work capit financ drawn end
hybrid capit relat two public hybrid bond one issu
nomin valu interest first call date
issu nomin valu interest first call date
assum compani pay back bond first call date
use cash syndic credit loan
sfr increas non-curr financi liabil
howev believ compani pay back
respect cash
pension liabil relat acquisit basf pharmaceut
busi contractu pension liabil without asset
counterpart common practic germani amount vari accord
number peopl pension portfolio technic term interest rate
siegfri good record free cash flow gener despit consist rise
dividend compani could also increas dividend coverag ratio believ without
acquisit compani continu keep ratio high continu
increas dividend figur
siegfri strong gener focus correspond fund alloc
compani follow clear set prioriti alloc fund main goal
maintain strong balanc sheet preserv financi flexibl order
abl react opportun achiev goal compani prioritis return
reinvest organ growth capital-expenditure mainten organ growth invest
dividend polici moder pay-out ratio distribut expect grow step-by-step
de-lever repay hybrid capit use syndic loan facil first hybrid
bond octob second hybrid bond octob see
opportunist line evolv strategi
first prioriti fund alloc reinvest organ growth siegfri need around
per year facil mainten intern growth
project around capex/sal around capex/depreci
assum absolut level increas slightli time without new
acquisit capex/sal ratio decreas period year
capex/depreci move toward
high industri compound-annual-growth-rate rel prematur steril fill market lead us believ
compani push mainli intern growth project categori invest
hameln irvin two site sterile-fil capabl
purpos
gmp site segreg cgmp product area high potenc
steril file line line ampoul vial
see much capital-expenditure impact gener current model assum
capital-expenditure grow lower rate compound-annual-growth-rate sale compound-annual-growth-rate
level sale rel low howev compani acquir
anoth site compani forecast model expect higher capital-expenditure
impact gener similar basf acquisit figur
howev expect return histor level acquisit
finalis case past
charl martineau pm univers toronto figur capital-expenditure
accord manag second prioriti fund alloc pay dividend
moder ratio also increas dividend per share absolut term given
compani abil gener past believ continu increas
dividend even sale stagnat temporarili
figur dividend yield pay-out ratio
net profit
oper cash flow
compani strong histori success acquisit
 full impact ebitda kick yr later
 hameln famili own
 debt-fre price acquisit eur
 financ privat place hybrid bond sfr public hybrid bond sfr
 acquisit price sfr paid cash
 product facil finish product tablet capsul
market fragment top particip account total
market current manag strong record pe activ
believ siegfri continu expand acquisit accord manag
prefer growth categori steril asept fill prefer us howev
manag view current market overvalu
even though model compani cash neg count hybrid
capit pension liabil debt see issu low
cost money moreov manag financi institut count hybrid bond
equiti consider lower net debt/ebitda ratio seen figur
enhanc manag confid siegfri capac term acquisit
net debt/ebitda ex hybrid incl pension
siegfri swiss-bas headquart zofingen switzerland found
zofingen compani convert joint stock corpor
share trade swiss exchang
siegfri employ around peopl oper global product
facil switzerland us malta china germani franc
siegfri strong record acquisit recent acquisit reflect
movement toward consolid industri one-stop-shop
siegfri acquir facil irvin hameln steril fill allow
compani integr portfolio expand high-growth field biolog
acquisit nantong china facilit backward integr give siegfri
flexibl produc api client low-cost countri acquisit basf api
busi allow siegfri reach critic size
focu cdm product servic
compani focus product drug substanc ds drug product dp
ds categori divid activ pharmaceut ingredi api
intermedi control substanc dp categori oral dosag form
steril fill siegfri offer exclus product ds dp also portfolio
offer multipl client assum split around
drug substanc ds sale
activ pharmaceut ingredi api key ingredi pharmaceut end
product caus direct effect treatment pharmaceut product may contain
one api siegfri produc fda-approv api
name suggest intermedi neither initi raw materi end product
rather interim product creat multi-step chemic reaction
control substanc chemic product product ownership use
regul nation intern level order control academ
commerci use prevent misus illeg trade siegfri market leader two
categori opiat deriv use pain manag predominantli cancer
treatment api use addict therapi methadon nicotin
drug product dp sale
api manufactur process liquid semisolid solid form
siegfri focus solid oral dosag form mainli tablet capsul howev
acquisit irvin hameln facil respect
siegfri enter field steril asept fill one demand
categori within galen product requir high-specif room good air
qualiti highly-train staff high-qual raw materi surfac accord
manag siegfri intend grow field mainli acquisit
siegfri global manufactur facil figur enabl compani
produc offer differ cost level mean product rang brand
exclus api multi-cli gener product global network also allow
client enter busi relationship one market entri point
top product account sale
respect six exclus protect product four gener
siegfri offer broad rang integr product servic offer thank
recent acquisit figur becom one-stop-shop mean
accompani client first stage develop molecul
manufactur commerci drug product/api compani underli busi
model includ contract develop manufactur in-hous develop co-
charl martineau pm univers toronto figur siegfri world-wide integr approach servic offer
siegfri integr suppli approach benefici client allow pharma
biotech compani reduc suppli chain complex minimis number
contractor deal save cost reduc time-to-market
drug avoid write-off drug failur cumul failur rate
phase approv benefit support pharma industri transit
outsourc develop manufactur activ third parti cdmo
figur benefit integr outsourc pharma compani
siegfri pure compani mean custom mainli global pharma
develop
manufactur figur total number custom around top
custom account sale
outsourc
charl martineau pm univers toronto figur siegfri custom base geographi net sale
life cycl drug expand sever year figur siegfri usual
manag team notabl ceo wolfgang wienand cfo reto
suter strong record privat equiti benefici given siegfri
growth strategi private-equity-domin landscap
mr wienand join siegfri start lead strategi legal
intellectu properti manag regulatori affair depart
also appoint head depart
mr suter join siegfri previous held senior financ posit privat
equiti industri notabl respons overse public take-over
subsequ delist restructur lonrho
figur board director
end term
peer global databas captur uniqu inform compani within
credit suiss coverag univers base relationship compani
custom supplier competitor databas built research analyst
insight regard relationship credit suiss cover compani global
compani form core peer databas also includ relationship
stock coverag
inform see novemb peer report chain reaction suppli
figur credit suiss peer map siegfri
sfr
net sale
net sale
net sale
net sale
net sale
net sale
net sale
share result associ compani
gross fix asset
invest fix asset
gross invest fix asset
net sale
gross intang asset
gross invest intang
sfr
short-term invest
accru incom prepaid expens
invest associ compani jv
financi non-curr asset
accru expens defer incom
sfr
chang provis
share result associ compani
net result dispos pp
net cash oper activ chang net wc
chang trade receiv
chang current asset
chang inventori
chang trade payabl
chang current liabil
payment provis
chang work capit per bs
net cash oper activ
purchas pp
proce dispos pp
purchas intang asset
proce dispos intang asset
acquisit group compani
invest financi fix asset
net cash invest activiit
issuanc hybrid capit
repay hybrid capit
chang financi liabil
repay current financi liabil
chang non-curr liabil
purchase/dispos treasurey share net
interest paid bank charg
dividend sharehold siegfri hold ag
oper cash flow
net cash financ activiit
unrealis fx gain loss cash cash equival
net chang cash cash equivalet
cash equival begin year
cash equival end year
compani mention price
